Pancreatic cancer drug trial halted over safety issues
Disease control
Terminated
This study tested a new drug called SOT102, alone or with standard chemotherapy, in 31 people with advanced pancreatic cancer. The goal was to find the safest dose and see if it helped shrink tumors. However, the trial was stopped early because of unexpected safety problems that …
Phase: PHASE1, PHASE2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC